Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2011年 / 46卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Is Dabigatran Cost Effective Compared With Warfarin for Stroke Prevention in Atrial Fibrillation? A Critically Appraised Topic
    Adcock, Amelia K.
    Lee-Iannotti, Joyce K.
    Aguilar, Maria I.
    Hoffman-Snyder, Charlene R.
    Wingerchuk, Dean M.
    Wellik, Kay E.
    Demaerschalk, Bart M.
    NEUROLOGIST, 2012, 18 (02) : 102 - 107
  • [2] Dabigatran as an alternative to warfarin in the prevention of thromboembolism in atrial fibrillation
    De Caterina, Raffaele
    Renda, Giulia
    GIORNALE ITALIANO DI CARDIOLOGIA, 2012, 13 (11) : 19S - 27S
  • [3] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [4] Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) : 570 - 571
  • [5] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [6] Clopidogrel Plus Aspirin is Cost-Effective for Stroke Prevention in Patients with Atrial Fibrillation in Whom Warfarin is Unsuitable
    Coleman, Craig I.
    Straznitskas, Andrew D.
    Sobieraj, Diana M.
    Kluger, Jeffrey
    CIRCULATION, 2011, 124 (21)
  • [7] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [8] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [9] Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
    Hongtao Wei
    Can Cui
    Xiangli Cui
    Yi Liu
    Dandan Li
    BMC Health Services Research, 21
  • [10] Dabigatran Challenges Warfarin's Superiority for Stroke Prevention in Atrial Fibrillation
    Schwartz, Neil E.
    Albers, Gregory W.
    STROKE, 2010, 41 (06) : 1307 - 1309
12345